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Oropharyngeal squamous-cell carcinomas caused by human papillomavirus (HPV)
are associated with favorable survival, but the independent prognostic significance
of tumor HPV status remains unknown.
Methods

We performed a retrospective analysis of the association between tumor HPV status
and survival among patients with stage III or IV oropharyngeal squamous-cell carcinoma who were enrolled in a randomized trial comparing accelerated-fractionation
radiotherapy (with acceleration by means of concomitant boost radiotherapy) with
standard-fractionation radiotherapy, each combined with cisplatin therapy, in patients with squamous-cell carcinoma of the head and neck. Proportional-hazards
models were used to compare the risk of death among patients with HPV-positive
cancer and those with HPV-negative cancer.
Results

The median follow-up period was 4.8 years. The 3-year rate of overall survival was
similar in the group receiving accelerated-fractionation radiotherapy and the group
receiving standard-fractionation radiotherapy (70.3% vs. 64.3%; P = 0.18; hazard ratio
for death with accelerated-fractionation radiotherapy, 0.90; 95% confidence interval
[CI], 0.72 to 1.13), as were the rates of high-grade acute and late toxic events. A total
of 63.8% of patients with oropharyngeal cancer (206 of 323) had HPV-positive tumors; these patients had better 3-year rates of overall survival (82.4%, vs. 57.1%
among patients with HPV-negative tumors; P<0.001 by the log-rank test) and, after
adjustment for age, race, tumor and nodal stage, tobacco exposure, and treatment
assignment, had a 58% reduction in the risk of death (hazard ratio, 0.42; 95% CI,
0.27 to 0.66). The risk of death significantly increased with each additional packyear of tobacco smoking. Using recursive-partitioning analysis, we classified our patients as having a low, intermediate, or high risk of death on the basis of four factors:
HPV status, pack-years of tobacco smoking, tumor stage, and nodal stage.
Conclusions

Tumor HPV status is a strong and independent prognostic factor for survival among
patients with oropharyngeal cancer. (ClinicalTrials.gov number, NCT00047008.)
24
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T

he majority of patients enrolled in
therapeutic trials for squamous-cell carcinoma of the head and neck have oropharyngeal squamous-cell carcinoma, which in a subgroup of these patients is caused by infection with
human papillomavirus (HPV).1 This subgroup is
defined by the presence of high-risk types of HPV
in tumor cells, predominantly HPV type 16 (HPV16). Expression of viral E6 and E7 oncoproteins
that inactivate the tumor-suppressor proteins p53
and the retinoblastoma protein (pRb), respectively, is necessary for malignant behavior of these
tumors.2
Several retrospective case series have shown
that among patients with oropharyngeal squa
mous-cell carcinoma, patients with HPV-positive
tumors have a better prognosis than patients with
HPV-negative tumors.3 Similar findings were
reported in a prospective analysis of data from a
clinical trial.4 Because of the small sample, however, other favorable prognostic factors associated
with tumor HPV status (e.g., early tumor stage or
young age) could not be ruled out as an explanation for the observed difference in survival.
We sought to evaluate the effect of tumor HPV
status on survival in patients with oropharyngeal
squamous-cell carcinoma who were enrolled in a
clinical trial of sufficient size to account for potentially confounding factors, including smoking
status. Our analysis was performed within a randomized clinical trial conducted by the Radiation
Therapy Oncology Group (RTOG; the RTOG 0129
study). Meta-analyses of clinical trials for patients
with locally advanced squamous-cell carcinoma of
the head and neck have shown that both accelerated-fractionation radiotherapy5 and concurrent
cisplatin-based chemotherapy improved survival as
compared with standard-fractionation radiotherapy alone.6 The RTOG 0129 study addressed the
question of whether accelerated-fractionation radiotherapy is superior to standard-fractionation
radiotherapy when each radiotherapy regimen is
combined with concurrent cisplatin therapy. We
report the results of this trial with an emphasis
on the effect of tumor HPV status on survival
among patients with oropharyngeal squamous-cell
carcinoma.

stitutional review boards at the participating centers. All patients provided written informed consent. The authors attest to the fidelity of the article
to the full protocol and statistical-analysis plan.
Eligibility criteria were the presence of untreated, pathologically confirmed, stage III or IV
squamous-cell carcinoma of the oral cavity, oro
pharynx, hypopharynx, or larynx without distant
metastases (M0)7; Zubrod’s performance status
score of 0 or 1 (asymptomatic or symptomatic but
ambulatory, respectively)8; age of 18 years or
older; and adequate bone marrow, hepatic, and
renal function. Lifetime tobacco exposure was determined at enrollment with the use of a standardized, self-administered questionnaire.
Patients were stratified on the basis of the tumor site (larynx vs. other), nodal stage (N0 vs. N1,
N2a, or N2b vs. N2c or N3), and Zubrod’s performance status score (0 vs. 1) and were randomly
assigned to receive high-dose cisplatin concurrently with either accelerated-fractionation radiotherapy (with the acceleration provided by means
of concomitant boost radiotherapy) or standardfractionation radiotherapy. The accelerated-fractionation radiotherapy consisted of the delivery
of 72 Gy in 42 fractions over a 6-week period, with
a concomitant boost of twice-daily irradiation for
12 treatment days (as previously reported9), and
standard-fractionation radiotherapy consisted of
the delivery of 70 Gy in 35 fractions (i.e., 2 Gy
per fraction) over a 7-week period. Intravenous
cisplatin was administered at a dose of 100 mg per
square meter of body-surface area on days 1 and
22 in the accelerated-fractionation radiotherapy
group and on days 1, 22, and 43 in the standardfractionation radiotherapy group.
Acute toxicity was evaluated weekly during
the period of therapy according to the Common
Terminology Criteria, version 2.0 (http://ctep
.info.nih.gov/protocolDevelopment/electronic_
applications/docs/ctcv20_4-30-992.pdf). To assess tumor status and late toxicity, according to
RTOG criteria,10 physical examinations and imaging studies were performed every 3 months for
the first 2 years, every 6 months during years
3 through 5, and annually thereafter.
Laboratory Studies

The analysis of tumor HPV status was restricted
to patients with oropharyngeal squamous-cell carStudy Protocol
cinoma because of the low prevalence of HPV
The RTOG 0129 study was registered with the among nonoropharyngeal squamous-cell carcinoNational Cancer Institute and approved by the in- mas.1 This post hoc subgroup analysis was not
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part of the study protocol. Formalin-fixed, paraffin-embedded tumor specimens were evaluated for
HPV-16 DNA with the use of the in situ hybridization–catalyzed signal-amplification method for
biotinylated probes (GenPoint, Dako).11 HPV-16–
negative tumors were further evaluated for 12 additional oncogenic HPV types (18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, and 68) by means of a biotin
ylated-probe cocktail (GenPoint HPV Probe Cocktail, Dako). An HPV-positive tumor was defined
as a tumor for which there was specific staining
of tumor-cell nuclei for HPV in either analysis.
Tumor p16 expression was evaluated by means
of immunohistochemical analysis with a mouse
monoclonal antibody (MTM Laboratories) visualized with use of an autostainer (Ventana XT,
Ventana) and a one-view secondary detection kit
(Ventana).12 Positive p16 expression was defined
as strong and diffuse nuclear and cytoplasmic
staining in 70% or more of the tumor cells.12
Study End Points

of

m e dic i n e

two groups with the use of the log-rank test. The
cumulative incidence method and Gray’s test were
used to estimate and compare rates of local–
regional relapse, distant metastases, and second
primary tumors.
Cox proportional-hazards models were used to
estimate hazard ratios; multivariable models were
developed by minimizing Akaike’s information
criterion. Cox regression was performed with the
use of data on tumor HPV status and smoking
status, for patients for whom these data were
available. Unadjusted and adjusted hazard ratios
for HPV-positive and HPV-negative status were
compared between the two groups to estimate
the proportion of the difference in survival that
was attributable to covariates. To investigate potential bias in estimates due to missing data on
HPV status, we repeated the analyses for the subgroup of patients with oropharyngeal squamouscell carcinoma and for the entire RTOG study
cohort (assuming the nonoropharyngeal squa
mous-cell carcinoma tumors were HPV-negative),
using values imputed with the Markov chain
Monte Carlo algorithm with a noninformative
prior distribution (SAS/STAT software, with SAS
OnlineDoc 9.1.3; SAS Institute). Twenty data sets
were created, and the resulting analyses were
combined per Rubin’s formula.16 Recursive-partitioning analysis (for censored survival data) was
performed with the use of S-Tree software (http://
peace.med.yale.edu/pub/stree) to identify the factors that were most influential for overall survival
and to permit the classification of patients with
oropharyngeal squamous-cell carcinoma as having a low, intermediate, or high risk of death.17

The primary end point was overall survival, defined
as the time from randomization to death. Secondary end points included progression-free survival,
defined as the time from randomization to death
or the first documented relapse, which was categorized as local–regional disease (tumor at the
primary site or regional nodes) or distant metastases. Death from the primary cancer without a
documented site of recurrence or death from an
unknown cause was considered death from local–
regional disease. Second primary tumors were
evaluated separately. Progression-free survival and
its components (local–regional disease and distant
metastases) were reported instead of protocolspecified secondary end points (e.g., disease-free
R e sult s
survival) to facilitate comparison with published
Characteristics of the Patients
meta-analyses.13
From July 2002 through May 2005, a total of 743
Statistical Analysis
patients were enrolled in the RTOG 0129 study
With a sample of 720 patients, the RTOG 0129 and randomly assigned to receive accelerated-fracstudy had 80% statistical power to detect a rela- tionation radiotherapy or standard-fractionation
tive reduction of 25% in the rate of death in the radiotherapy. Analyses were restricted to the 721
accelerated-fractionation radiotherapy group as patients who met the protocol study criteria (360
compared with the standard-fractionation radio- patients in the accelerated-fractionation radiothertherapy group, assuming a 2-year rate of overall apy group and the 361 patients in the standardsurvival of 45% in the standard-fractionation ra- fractionation radiotherapy group); of the remaindiotherapy group,14,15 with the use of a one-sided ing 22 patients, 17 were found to be ineligible
test at the 0.05 significance level.
and 5 withdrew consent. The baseline characRates of overall survival and progression-free teristics of the two groups are listed in Table 1.
survival were estimated by means of the Kaplan–
The majority of enrolled patients (60.1% [433
Meier method and were compared between the of 721]) had oropharyngeal squamous-cell carci26
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noma, and HPV status was determined in 74.6%
of these patients (323 of 433). Tumor specimens
were not available for study in 94 patients, and
tissue specimens from 16 patients did not contain tumor tissue. No significant differences in
baseline characteristics, overall survival, or progression-free survival were found between patients
in whom HPV status was determined and those
in whom it was not, arguing against significant
selection bias (see the Supplementary Appendix,
available with the full text of this article at NEJM
.org). HPV DNA was detected in 63.8% of patients’
tumors (206 of the 323) by means of in situ hybridization, and 96.1% of the samples (198 of 206)
were positive for HPV-16.
HPV-positive oropharyngeal cancer was more
common among patients who had never smoked
and those with a lower number of cumulative
pack-years of tobacco smoking than among those
with a history of heavier smoking and was also
significantly associated with several favorable
prognostic factors, including younger age, white
race, better performance status, absence of anemia, and smaller primary tumors (Table 1). The
two treatment groups were balanced with regard
to tumor HPV status.
Survival and Toxicity

There were no significant differences between the
accelerated-fractionation radiotherapy group and
the standard-fractionation radiotherapy group with
regard to the rate of death within 30 days after
the start of therapy (3.3% and 1.9%, respectively;
P = 0.26) or the overall rates of grade 3 or 4 acute
toxic events (80.0% and 83.7%, respectively;
P = 0.21) and late toxic events (25.7% and 21.1%,
respectively; P = 0.18). At the data cutoff point
(August 2009), 418 patients were alive. After a
median follow-up of 4.8 years (range, 0.3 to 6.5),
there was no significant difference in the 3-year
rate of overall survival between the acceleratedfractionation radiotherapy group (70.3%; 95% confidence interval [CI], 65.6 to 75.1) and the standardfractionation radiotherapy group (64.3%; 95% CI,
59.3 to 69.2; P = 0.18). There was a nonsignificant
reduction of 10% in the risk of death for the accelerated-fractionation radiotherapy group as compared with the standard-fractionation radiotherapy group (hazard ratio, 0.90; 95% CI, 0.72 to
1.13), with a similar reduction in the subgroup of
patients with HPV-positive cancer (11%; hazard ratio, 0.89; 95% CI, 0.51 to 1.55) and in the subgroup
with HPV-negative cancer (9%; hazard ratio, 0.91;
n engl j med 363;1

95% CI, 0.69 to 1.19). The accelerated-fractionation
radiotherapy group and the standard-fractionation
radiotherapy group did not differ significantly with
regard to progression-free survival or the pattern
of relapse (see the Supplementary Appendix).
HPV Status and Survival

For analysis of the association of tumor HPV status
with survival, we combined the data for all patients with oropharyngeal squamous-cell carcinoma, since the survival rates were similar in the two
treatment groups. In a Kaplan–Meier analysis, patients with HPV-positive cancer had better overall
survival and progression-free survival than patients with HPV-negative cancer (P<0.001 for both
end points, by the log-rank test). The 3-year rates
of overall survival were 82.4% (95% CI, 77.2 to 87.6)
in the HPV-positive subgroup and 57.1% (95% CI,
48.1 to 66.1) in the HPV-negative subgroup (Fig.
1A), and the 3-year rates of progression-free survival were 73.7% (95% CI, 67.7 to 79.8) and 43.4%
(95% CI, 34.4 to 52.4), respectively (Fig. 1B).
In the multivariable analysis, age, race, performance status, tumor stage, nodal stage, and
number of pack-years of tobacco smoking were
also significant determinants of overall survival
and progression-free survival (Table 2). By comparing the unadjusted hazard ratios for HPV-positive versus HPV-negative tumor status (hazard ratio
for death, 0.38; 95% CI, 0.26 to 0.55; and hazard
ratio for relapse or death, 0.40; 95% CI, 0.29 to
0.57) (Fig. 1A and 1B) with the corresponding
adjusted hazard ratios (provided below), we estimated that these factors accounted for a relative
difference of approximately 9% in the rates of
overall survival and progression-free survival between patients with HPV-positive and those with
HPV-negative oropharyngeal squamous-cell carcinoma. Nonetheless, after this adjustment, patients
with HPV-positive tumors had a 58% reduction in
the risk of death as compared with patients with
HPV-negative tumors (hazard ratio, 0.42; 95% CI,
0.27 to 0.66) and a 51% reduction in the risk of
relapse or death (hazard ratio, 0.49; 95% CI, 0.33
to 0.74) (Table 2). After imputation for missing
data, the results were similar (Table 2).
Tumors were evaluated for the expression of not
only HPV but also a known biomarker of HPVoncoprotein function, the cyclin-dependent–kinase
inhibitor p16, which is induced as a consequence
of pRb inactivation by the HPV E7 oncoprotein18
but is minimally detectable in HPV-negative tumors because of epigenetic or genetic silencing.19
nejm.org
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The presence of HPV DNA and the presence of
p16 expression in tumors had very good agreement (kappa = 0.80; 95% CI, 0.73 to 0.87). Using
p16 expression as a stratification factor, we found
differences in overall and progression-free survival
that were consistent with those based on HPV
status. In unadjusted analyses, the 3-year rate of
overall survival was 83.6% (95% CI, 78.7 to 88.6)
in the subgroup that was positive for p16 expression and 51.3% (95% CI, 41.5 to 61.0) in the subgroup that was negative for p16 expression (haz-

of

m e dic i n e

ard ratio for death with positive p16 expression,
0.29; 95% CI, 0.20 to 0.43) (Fig. 1C); the 3-year rate
of progression-free survival was 74.4% (95% CI,
68.5 to 80.2) and 38.4% (95% CI, 28.9 to 47.9),
respectively (hazard ratio for relapse or death with
positive p16 expression, 0.33; 95% CI, 0.24 to 0.46)
(Fig. 1D). After adjustment for other factors, the
corresponding hazard ratio for death was 0.33
(95% CI, 0.21 to 0.53), and the corresponding hazard ratio for relapse or death was 0.42 (95% CI,
0.28 to 0.64).

Table 1. Baseline Characteristics of the Study Patients and Their Tumors, According to Patient Group.*
Characteristic

Patients with Oropharyngeal Cancer
and Known Tumor HPV Status

All Study Patients
StandardFractionation
Radiotherapy and
Cisplatin (N = 361)

AcceleratedFractionation
Radiotherapy and
Cisplatin (N = 360)

HPV-Positive
(N = 206)

HPV-Negative
(N = 117)

Treatment assignment — no. (%)
Standard-fractionation radiotherapy
and cisplatin
Accelerated-fractionation radiotherapy
and cisplatin

0.86
361 (100)

0

106 (51.5)

59 (50.4)

0

360 (100)

100 (48.5)

58 (49.6)

Age — yr

0.02

Median

56.0

55.0

53.5

57.0

Range

34–82

26–82

31–78

37–82

Sex — no. (%)
Male
Female

0.10
309 (85.6)

288 (80.0)

178 (86.4)

93 (79.5)

52 (14.4)

72 (20.0)

28 (13.6)

24 (20.5)

290 (80.3)

299 (83.1)

190 (92.2)

88 (75.2)

71 (19.7)

61 (16.9)

16 (7.8)

29 (24.8)

Race — no. (%)‡
White
Nonwhite

P Value†

<0.001

Zubrod’s performance status score — no. (%)§

0.03

0

206 (57.1)

211 (58.6)

141 (68.4)

66 (56.4)

1

155 (42.9)

149 (41.4)

65 (31.6)

51 (43.6)

No

250 (69.3)

247 (68.6)

161 (78.2)

75 (64.1)

Yes

111 (30.7)

113 (31.4)

45 (21.8)

42 (35.9)

Oral cavity

24 (6.6)

18 (5.0)

0

Oropharynx

Anemia — no. (%)¶

0.006

Primary site — no. (%)
0

216 (59.8)

217 (60.3)

206 (100)

Hypopharynx

31 (8.6)

27 (7.5)

0

117 (100)
0

Larynx

90 (24.9)

98 (27.2)

0

0

Tumor stage — no. (%)

28

0.006

T2

69 (19.1)

99 (27.5)

71 (34.5)

28 (23.9)

T3

169 (46.8)

159 (44.2)

84 (40.8)

43 (36.8)

T4

123 (34.1)

102 (28.3)

51 (24.8)

46 (39.3)
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Table 1. (Continued.)
Characteristic

Patients with Oropharyngeal Cancer
and Known Tumor HPV Status

All Study Patients
StandardFractionation
Radiotherapy and
Cisplatin (N = 361)

AcceleratedFractionation
Radiotherapy and
Cisplatin (N = 360)

HPV-Positive
(N = 206)

HPV-Negative
(N = 117)

Nodal stage — no. (%)

P Value†
0.46

N0

67 (18.6)

69 (19.2)

15 (7.3)

9 (7.7)

N1

54 (15.0)

53 (14.7)

22 (10.7)

24 (20.5)

N2a

28 (7.8)

32 (8.9)

25 (12.1)

12 (10.3)

N2b

94 (26.0)

95 (26.4)

78 (37.9)

29 (24.8)

N2c

89 (24.7)

84 (23.3)

44 (21.4)

34 (29.1)

N3

29 (8.0)

27 (7.5)

22 (10.7)

9 (7.7)

III

77 (21.3)

81 (22.5)

25 (12.1)

19 (16.2)

IV

284 (78.7)

279 (77.5)

181 (87.9)

98 (83.8)

AJCC stage — no. (%)

0.30

Tobacco exposure — no. (%)

<0.001

Never smoked

44 (12.2)

69 (19.2)

59 (28.6)

14 (12.0)

Former smoker

191 (52.9)

183 (50.8)

110 (53.4)

54 (46.2)

Current smoker

83 (23.0)

68 (18.9)

24 (11.7)

32 (27.4)

Unknown

43 (11.9)

40 (11.1)

13 (6.3)

17 (14.5)

Tobacco-smoking history — no. of pack-years‖

<0.001

Median

33

24

12.2

36.5

Range

0–137.5

0–152.0

0–152.0

0–96.0

HPV status of primary oropharyngeal tumor
— no./total no. (%)
Positive

106/216 (49.1)

100/217 (46.1)

206/206 (100)

0

Negative

59/216 (27.3)

58/217 (26.7)

0

117/117 (100)

Unknown

51/216 (23.6)

59/217 (27.2)

0

0

p16 Expression in oropharyngeal primary
tumor — no./total no. (%)

<0.001

Positive

114/216 (52.8)

101/217 (46.5)

192/206 (93.2)

22/117 (18.8)

Negative

48/216 (22.2)

53/217 (24.4)

7/206 (3.4)

94/117 (80.3)

Unknown

54/216 (25.0)

63/217 (29.0)

7/206 (3.4)

1/117 (0.9)

* AJCC denotes the American Joint Committee on Cancer, and HPV human papillomavirus.
† P values were calculated with the use of Pearson’s chi-square test for all comparisons, except age and pack-years, for which the Kolmogorov–
Smirnov test was used, and tumor stage and nodal stage, for which the Kruskal–Wallis test was used.
‡ Race was self-reported.
§ Zubrod’s performance status scores of 0 and 1 correspond to asymptomatic performance and symptomatic but ambulatory performance,
respectively.
¶ Anemia was defined as a hemoglobin level of 13.5 g per deciliter or less for men and 12.5 g per deciliter or less for women.
‖ A pack-year is defined as the equivalent of smoking one pack of cigarettes per day for 1 year. Data on pack-years were missing for 28 of the
206 patients (13.6%) with HPV-positive tumors and 29 of the 117 patients (24.8%) with HPV-negative tumors.

Tobacco smoking was also independently associated with overall survival and progression-free
survival both in the subgroup of patients with
oropharyngeal squamous-cell carcinoma and in
n engl j med 363;1

the entire study population (Table 2). The risks of
death and cancer relapse or death significantly
increased by 1% for each additional pack-year of
tobacco smoking (Table 2), and the magnitude of
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Figure 1. Kaplan–Meier Estimates of Survival among the Study Patients with Oropharyngeal Cancer, According to Tumor HPV Status
or p16-Expression Status.
Data on overall survival and progression-free survival are shown according to stratification on the basis of tumor HPV status (Panels A
and B, respectively) or p16-expression status (Panels C and D, respectively). The Kaplan–Meier curves are shown in black, and the associated 95% confidence intervals in gray. Patients with HPV-positive tumors had significantly better overall survival and progression-free
survival than did patients with HPV-negative tumors (P<0.001 for both comparisons by the two-sided log-rank test). The 3-year rates of
overall survival were 82.4% (95% CI, 77.2 to 87.6) in the HPV-positive subgroup and 57.1% (95% CI, 48.1 to 66.1) in the HPV-negative
subgroup (Panel A), and the 3-year rates of progression-free survival were 73.7% (95% CI, 67.7 to 79.8) and 43.4% (95% CI, 34.4 to 52.4),
respectively (Panel B). The 3-year absolute benefit of HPV-positive status for overall survival was 25 percentage points (95% CI, 11 to
40), and the absolute benefit for progression-free survival was 30 percentage points (95% CI, 15 to 45). The results were similar with
stratification according to p16-expression status. The 3-year rates of overall survival were 83.6% (95% CI, 78.7 to 88.6) in the subgroup
that was positive for p16 expression and 51.3% (95% CI, 41.5 to 61.0) in the subgroup that was negative for p16 expression (P<0.001)
(Panel C), and the 3-year rates of progression-free survival were 74.4% (95% CI, 68.5 to 80.2) and 38.4% (95% CI, 28.9 to 47.9), respectively (P<0.001) (Panel D).

the tobacco effect was similar for patients with
In an analysis of patterns of treatment failure
HPV-positive cancer (hazard ratio, 1.01; 95% CI, among patients with oropharyngeal squamous-cell
1.00 to 1.02) and those with HPV-negative cancer carcinoma, the 3-year rate of local–regional dis(hazard ratio, 1.01; 95% CI, 1.00 to 1.03).
ease, but not distant metastasis, was significantly
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Table 2. Hazard Ratios for Overall and Progression-free Survival, According to Patient Group.
Covariate

All Patients, with Data
Imputed (N = 721)

Patients with Oropharyngeal Cancer
Complete Data (N = 266)
hazard ratio
(95% CI)

Data Imputed (N = 433)

P value

hazard ratio
(95% CI)

P value

hazard ratio
(95% CI)

P value

Treatment assignment (accelerated- vs. standard- 1.24 (0.81–1.89)
fractionation radiotherapy)

0.32

1.09 (0.78–1.52)

0.61

0.98 (0.78–1.23)

0.87

Age (>50 yr vs. ≤50 yr)

1.62 (0.96–2.74)

0.07

1.69 (1.12–2.56)

0.01

1.35 (1.02–1.80)

0.03

Race (nonwhite vs. white)

1.57 (0.89–2.75)

0.12

2.13 (1.39–3.25)

<0.001

1.56 (1.18–2.05)

0.002

Tumor stage (T4 vs. T2–T3)

2.15 (1.40–3.29) <0.001

2.00 (1.43–2.80)

<0.001

1.85 (1.46–2.34)

<0.001

Nodal stage (N2b–N3 vs. N0–N2a)

1.99 (1.24–3.21)

0.005

1.91 (1.30–2.79)

<0.001

1.68 (1.33–2.14)

<0.001

Pack-years of smoking (per increase of 1 yr)

1.01 (1.00–1.02)

0.003

1.01 (1.01–1.02)

<0.001

1.01 (1.00–1.01)

0.002

HPV status (positive vs. negative)

0.42 (0.27–0.66) <0.001

0.50 (0.33–0.76)

0.002

0.41 (0.29–0.57)

<0.001

HPV status (negative vs. positive)

2.38 (1.51–3.74) <0.001

2.00 (1.31–3.06)

0.002

2.44 (1.75–3.41)

<0.001

Overall survival

Progression-free survival
Treatment assignment (accelerated- vs. standard- 1.19 (0.81–1.73)
fractionation radiotherapy)

0.38

1.12 (0.83–1.50)

0.46

1.06 (0.86–1.31)

0.58

Age (>50 yr vs. ≤50 yr)

1.69 (1.05–2.72)

0.03

1.73 (1.20–2.50)

0.003

1.39 (1.08–1.80)

0.01

Race (nonwhite vs. white)

1.43 (0.85–2.39)

0.18

1.66 (1.13–2.44)

0.01

1.41 (1.09–1.82)

0.009

Zubrod’s performance status score (1 vs. 0)

1.42 (0.97–2.09)

0.07

1.44 (1.05–1.96)

0.02

1.51 (1.22–1.88)

<0.001

Tumor stage (T4 vs. T2–T3)

1.48 (1.00–2.20)

0.05

1.32 (0.96–1.80)

0.08

1.43 (1.15–1.78)

0.001

Nodal stage (N2b–N3 vs. N0–N2a)

1.60 (1.06–2.42)

0.03

1.51 (1.09–2.10)

0.01

1.54 (1.24–1.91)

<0.001

Pack-years of smoking (per increase of 1 yr)

1.01 (1.00–1.02)

0.002

1.01 (1.00–1.01)

0.002

1.01 (1.00–1.01)

0.002

HPV status (positive vs. negative)

0.49 (0.33–0.74) <0.001

0.53 (0.37–0.76)

<0.001

0.48 (0.36–0.65)

<0.001

HPV status (negative vs. positive)

2.02 (1.35–3.03) <0.001

1.88 (1.31–2.70)

<0.001

2.06 (1.55–2.75)

<0.001

* HPV denotes human papillomavirus. Estimates for each covariate have been adjusted for all other covariates listed. The data that were imputed (with the use of 20 imputations) were data on HPV status and number of pack-years. Missing HPV status was imputed for 110 patients with primary oropharyngeal cancer. Patients with a nonoropharyngeal primary site were assumed to have HPV-negative tumors.
Missing number of pack-years was imputed for a total of 163 patients, 80 of whom had oropharyngeal cancer. Using the unadjusted hazard
ratio for death among patients with HPV-negative (vs. HPV-positive) tumors of 2.62, we estimated that the covariates could account for 9%
(100 × [1 – 2.38 ÷ 2.62]) of the different in survival between patients with HPV-positive tumors and those with HPV-negative tumors in the
model with complete data and up to 25% (100 × [1–2.00 ÷ 2.62]) in the model with imputations. In a model with data from all patients, with
HPV-positive oropharyngeal squamous-cell carcinoma as the reference group, HPV-negative oropharyngeal squamous-cell carcinoma and
nonoropharyngeal squamous-cell carcinoma were associated with similar hazard ratios for death (2.29 and 2.55, respectively) and relapse or
death (2.02 and 2.09, respectively).

lower for patients with HPV-positive tumors than
for those with HPV-negative tumors (13.6% vs.
35.1%, P<0.001) (Table 3). In addition, the cumulative incidence of second primary tumors was
significantly lower among patients with HPV-positive tumors, largely because of lower rates of
smoking-related cancer (Table 3).
Recursive-partitioning analysis showed that the
HPV status of the tumor was the major determinant of overall survival, followed by the number
of pack-years of tobacco smoking (≤10 vs. >10)
and then nodal stage (N0 to N2a vs. N2b to N3),
n engl j med 363;1

for HPV-positive tumors, or tumor stage (T2 or T3
vs. T4), for HPV-negative tumors (Fig. 2A). This
analysis classified patients with oropharyngeal
squamous-cell carcinoma into three categories
with respect to the risk of death: low risk, with
a 3-year rate of overall survival of 93.0%; intermediate risk, with a 3-year rate of 70.8% (hazard ratio
for the comparison with low risk, 3.54; 95% CI,
1.91 to 6.57); and high risk, with a 3-year rate of
46.2% (hazard ratio for the comparison with low
risk, 7.16; 95% CI, 3.97 to 12.93) (Fig. 2B). Patients
with HPV-positive tumors were considered to be
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Table 3. Survival Estimates, Causes of Death, and Patterns of Treatment Failure in Patients with Oropharyngeal Cancer,
According to Tumor HPV Status.*
Variable
Overall survival at 3 yr — % (95% CI)

HPV-Positive
(N = 206)

HPV-Negative
(N = 117)

P Value†

82.4 (77.2–87.6)

57.1 (48.1–66.1)

<0.001

Cause of death — no. of patients/total no. (%)

0.67

Primary cancer

25/50 (50.0)

29/58 (50.0)

Second primary tumor

4/50 (8.0)

8/58 (13.8)

Protocol treatment

1/50 (2.0)

0/58

Nonprotocol treatment
Cause unrelated to cancer or treatment
Unknown

1/50 (2.0)

1/58 (1.7)

10/50 (20.0)

8/58 (13.8)

9/50 (18.0)

12/58 (20.7)

Progression-free survival at 3 yr — % (95% CI)

73.7 (67.7–79.8)

43.4 (34.4–52.4)

<0.001

Local–regional relapse at 3 yr — % (95% CI)

13.6 (8.9–18.3)

35.1 (26.4–43.8)

<0.001

8.7 (4.9–12.6)

14.6 (8.1–21.1)

0.23

Distant metastasis at 3 yr — % (95% CI)
Type of first treatment failure — no. of patients/total no. (%)

0.55

Local–regional disease

26/66 (39.4)

Distant metastasis

21/66 (31.8)

33/72 (45.8)
17/72 (23.6)

Death, no documented progression

19/66 (28.8)

22/72 (30.6)

Second primary tumor at 3 yr — % (95% CI)

5.9 (2.6–9.1)

14.6 (8.1–21.0)

Head and neck

5/19 (26.3)

5/21 (23.8)

Lung

8/19 (42.1)

9/21 (42.9)

Prostate

2/19 (10.5)

2/21 (9.5)

Colon

0/19

1/21 (4.8)

Rectum

0/19

1/21 (4.8)

Kidney

0/19

1/21 (4.8)

Site of second primary tumor — no. of patients/total no. (%)

Breast

0.02
0.91

0/19

1/21 (4.8)

Skin

3/19 (15.8)

1/21 (4.8)

Unknown

1/19 (5.3)

0/21

* HPV denotes human papillomavirus.
† P values were calculated with the use of Gray’s test, except for overall and progression-free survival, for which the logrank test was used, and cause of death, type of first treatment failure, and site of second primary tumor, for which
Pearson’s chi-square test was used. The P value for the cause of death was calculated with primary cancer, protocol
treatment, and nonprotocol treatment combined. The P value for the site of a second primary tumor was calculated
with head and neck cancer and lung cancer (both of which are considered to be related to smoking) combined.

at low risk, with the exception of smokers with a
high nodal stage (i.e., N2b to N3), who were considered to be at intermediate risk; patients with
HPV-negative tumors were considered to be at high
risk, with the exception of nonsmokers with tumors of stage T2 or T3, who were considered to
be at intermediate risk.

for overall survival and progression-free survival
among patients with oropharyngeal squamous-cell
carcinomas, which is consistent with the hypothesis that HPV-positive and HPV-negative oropharyngeal squamous-cell carcinomas are distinct and
have different causes,20 risk-factor profiles,1 and
survival outcomes. On the basis of our data, we
believe that future clinical trials should be designed specifically for patients with HPV-positive
Discussion
or HPV-negative squamous-cell carcinoma of the
This study provides strong evidence that tumor head and neck or patients who have been stratiHPV status is an independent prognostic factor fied according to HPV status. Moreover, addition32
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al information could be gleaned from completed
clinical trials, by means of reanalysis, to determine whether imbalances in tumor HPV status
between treatment groups affected the outcomes
and thus the therapeutic implications.
Our analysis of the association of HPV status
with survival was performed in a clinical trial of
locally advanced squamous-cell carcinoma of the
head and neck that did not show a significant difference in overall survival between a concomitantboost accelerated-fractionation regimen of radiotherapy and a standard-fractionation regimen,
combined with concurrent, high-dose cisplatin.
Therefore, either regimen could serve as the comparison for a new therapy being investigated.
We observed strong agreement between tumor
HPV status, as determined by in situ hybridization,
and expression of p16, an established biomarker
for the function of the HPV E7 oncoprotein. Our
HPV-16 in situ hybridization assay has sensitivity
for single viral copies, and a positive result is
strongly correlated with expression of the HPV
E6 and E7 oncogenes — the standard for defining a tumor as being associated with HPV.21,22
A limitation of our method is the unknown senn engl j med 363;1

A
266 Patients with oropharyngeal cancer, known tumor
HPV status, and known number of pack-years of smoking

178 Had HPVpositive tumors

88 Had ≤10
pack-years

88 Had HPVnegative tumors

90 Had >10
pack-years

26 Had
N0–N2a
cancer

114 of 266 (42.9%) were
at low risk

23 Had ≤10
pack-years

64 Had
N2b–N3
cancer

15 Had
T2–T3
tumors

65 Had >10
pack-years

8 Had
T4
tumors

79 of 266 (29.7%) were
at intermediate risk

73 of 266 (27.4%) were
at high risk

B
100
Low risk

Overall Survival (%)

Figure 2. Classification of the Study Patients into Riskof-Death Categories and Kaplan–Meier Estimates of
Overall Survival According to Those Categories.
Recursive-partitioning analysis was used to identify
prognostic factors with the most influential predictive
significance in a proportional-hazards model of overall
survival and to classify patients into categories of low,
intermediate, or high risk of death. The prognostic factors in the analysis were age, tumor stage, nodal stage,
race, smoking status, HPV status, anemia status, performance status, treatment assignment, and sex. Panel
A shows the resulting classifications. Panel B shows
data for overall survival in the classified patients. The
Kaplan–Meier curves are shown in black, and the associated 95% confidence intervals in gray. The 3-year
rates of overall survival were 93.0% (95% CI, 88.3 to
97.7) in the low-risk group, 70.8% (95% CI, 60.7 to
80.8) in the intermediate-risk group, and 46.2% (95%
CI, 34.7 to 57.7) in the high-risk group. Hazard ratios
for death among the 266 patients for whom the risk
classification could be made on the basis of the recorded data and among all 433 patients with oropharyngeal cancer (after missing data on HPV status and
number of pack-years were estimated with the use of
statistical imputation) were as follows: 3.54 (95% CI,
1.91 to 6.57) and 2.67 (95% CI, 1.54 to 4.62), respectively, in the intermediate-risk group versus the lowrisk group; and 7.16 (95% CI, 3.97 to 12.93) and 5.23
(95% CI, 3.14 to 8.73), respectively, in the high-risk
group versus the low-risk group.
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sitivity of the probe cocktail for non–HPV-16 types,
which account for an estimated 5 to 10% of HPVpositive oropharyngeal squamous-cell carcinomas.23 Thus, the misclassification of HPV-positive
tumors as HPV-negative tumors probably explains
the slightly larger reduction in the risk of death
when the analysis was based on status with respect
to p16 expression rather than HPV presence.
A strength of the p16-expression assay is that it
is not specific for HPV type, unlike the in situ
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hybridization assays; therefore, p16-expression status is a very good surrogate for tumor HPV status.
The superior prognosis for HPV-positive oro
pharyngeal squamous-cell carcinoma, as compared with that for the HPV-negative cancer, appears to have multifactorial underpinnings. Known
favorable prognostic factors associated with the
HPV-positive subgroup account for approximately
10% of the detected difference in outcome. The
higher survival rate among patients with HPVpositive cancer is due in part to greater local–
regional control, reflecting higher intrinsic sensitivity to radiation or better radiosensitization with
the use of cisplatin. Although rates of response
to induction chemotherapy are higher among patients with HPV-positive tumors than among those
with HPV-negative tumors,4 single-agent cisplatin
therapy did not appear to differentially affect the
elimination of occult distant metastases. Second
primary tumors, which are largely related to smoking, were less frequent among patients with HPVpositive tumors, a finding that is consistent with
the lower exposure to tobacco in this subgroup.
However, the rates of death from second primary
tumors were similar in the HPV-positive and HPVnegative subgroups and therefore do not account
for the overall differences in survival rates.
Our data clearly indicate that HPV status and
status with respect to tobacco smoking are major
independent prognostic factors for patients with
oropharyngeal squamous-cell carcinoma, probably because they determine the molecular profile
of the cancer and thus the response to therapy.
Although HPV-positive oropharyngeal squamouscell carcinoma is genetically distinct from the
HPV-negative cancer with respect to patterns of
loss of heterozygosity,24 chromosomal abnormalities,25,26 and gene-expression profiles27 and is inversely correlated with biomarkers for a poor
prognosis in squamous-cell carcinoma of the head
and neck (e.g., p53 mutations28 or expression of
epidermal growth factor receptor29), no specific
mechanism has been shown to explain the higher
rates of response to radiation therapy and chemotherapy among patients with HPV-positive cancer.4
Epidemiologic data indicate that tobacco smoking is not a strong cofactor for the development
of HPV-positive oropharyngeal squamous-cell carcinoma.1 Nevertheless, our data reveal that the
biologic behavior of an HPV-positive tumor may
be altered by tobacco use. Genetic alterations in-

34
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duced by tobacco-associated carcinogens may render HPV-positive tumors less responsive to therapy. The likelihood of such genetic alterations
appears to increase as the number of pack-years
of tobacco smoking increases (Table 2). The cutoff point of 10 pack-years, which was the best
predictor of survival in our recursive-partitioning
analysis, may be more useful than a continuum
for the design of future risk-based clinical trials
but will require further validation.
The extent to which the superior survival for a
patient with HPV-positive oropharyngeal squamouscell carcinoma depends on the administered therapy is unclear. Published data indicate that tumor
HPV status is a strong and consistent determinant
of superior survival, regardless of treatment strategy (e.g., surgery,30 radiation therapy,31,32 concurrent chemoradiation therapy [in this study], or
induction chemotherapy plus concurrent chemoradiation therapy4,33), with 5-year survival rates
among patients with HPV-positive tumors of approximately 75 to 80%, versus 45 to 50% among
patients with HPV-negative tumors.
Though no direct evidence from formal clinical trials exists to guide treatment decisions for
the individual patient on the basis of tumor HPV
status, this study provides a direction for future
clinical research. A combination of tumor HPV
status, pack-years of tobacco smoking, and cancer
stage may be used to classify patients as having
a low, intermediate, or high risk of death. Whether patients with HPV-positive tumors who are
considered to be in the low-risk category can be
spared the long-term complications of intensive,
multimodal therapy without compromising their
survival is now a highly relevant clinical question.
In contrast, such a strategy would be inappropriate for the 36% of patients with HPV-positive tumors who are in the intermediate-risk group, for
whom the 3-year rate of overall survival (71%, with
an even lower rate of progression-free survival) is
unacceptable. Unfortunately, patients in the highrisk group have an extremely poor prognosis and
thus should be offered enrollment in trials testing more intensive investigational therapies. Should
our risk model be validated in other cohorts, it
will be important to incorporate tumor HPV
status and tobacco exposure as nonanatomical
determinants of risk classification and therapy
selection for patients with oropharyngeal squa
mous-cell carcinoma.
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